Cargando…

Current and future treatment options in SIADH

The treatment of hyponatraemia due to SIADH is not always as straightforward as it seems. Although acute treatment with hypertonic saline and chronic treatment with fluid restriction are well established, both approaches have severe limitations. These limitations are not readily overcome by addition...

Descripción completa

Detalles Bibliográficos
Autores principales: Zietse, Robert, van der Lubbe, Nils, Hoorn, Ewout J.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762827/
https://www.ncbi.nlm.nih.gov/pubmed/19881932
http://dx.doi.org/10.1093/ndtplus/sfp154
_version_ 1782172956584050688
author Zietse, Robert
van der Lubbe, Nils
Hoorn, Ewout J.
author_facet Zietse, Robert
van der Lubbe, Nils
Hoorn, Ewout J.
author_sort Zietse, Robert
collection PubMed
description The treatment of hyponatraemia due to SIADH is not always as straightforward as it seems. Although acute treatment with hypertonic saline and chronic treatment with fluid restriction are well established, both approaches have severe limitations. These limitations are not readily overcome by addition of furosemide, demeclocycline, lithium or urea to the therapy. In theory, vasopressin-receptor antagonists would provide a more effective method to treat hyponatraemia, by virtue of their ability to selectively increase solute-free water excretion by the kidneys (aquaresis). In this review we explore the limitations of the current treatment of SIADH and describe emerging therapies for the treatment of SIADH-induced hyponatraemia.
format Text
id pubmed-2762827
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-27628272009-11-01 Current and future treatment options in SIADH Zietse, Robert van der Lubbe, Nils Hoorn, Ewout J. NDT Plus Original Article The treatment of hyponatraemia due to SIADH is not always as straightforward as it seems. Although acute treatment with hypertonic saline and chronic treatment with fluid restriction are well established, both approaches have severe limitations. These limitations are not readily overcome by addition of furosemide, demeclocycline, lithium or urea to the therapy. In theory, vasopressin-receptor antagonists would provide a more effective method to treat hyponatraemia, by virtue of their ability to selectively increase solute-free water excretion by the kidneys (aquaresis). In this review we explore the limitations of the current treatment of SIADH and describe emerging therapies for the treatment of SIADH-induced hyponatraemia. Oxford University Press 2009-11 /pmc/articles/PMC2762827/ /pubmed/19881932 http://dx.doi.org/10.1093/ndtplus/sfp154 Text en © The Author 2009. Published by Oxford University Press [on behalf of ERA-EDTA]. http://creativecommons.org/licenses/by-nc/2.0/uk/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Zietse, Robert
van der Lubbe, Nils
Hoorn, Ewout J.
Current and future treatment options in SIADH
title Current and future treatment options in SIADH
title_full Current and future treatment options in SIADH
title_fullStr Current and future treatment options in SIADH
title_full_unstemmed Current and future treatment options in SIADH
title_short Current and future treatment options in SIADH
title_sort current and future treatment options in siadh
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762827/
https://www.ncbi.nlm.nih.gov/pubmed/19881932
http://dx.doi.org/10.1093/ndtplus/sfp154
work_keys_str_mv AT zietserobert currentandfuturetreatmentoptionsinsiadh
AT vanderlubbenils currentandfuturetreatmentoptionsinsiadh
AT hoornewoutj currentandfuturetreatmentoptionsinsiadh